Labcorp is offering nationwide access to Roche’s FDA-approved VENTANA PTEN (SP218) RxDx Assay, the first IHC companion diagnostic to identify PTEN protein loss in prostate cancer and guide eligibility for combination therapy with capivasertib.
The digital pathology platform provides patient-specific risk estimates to help clinicians tailor treatment for metastatic hormone-sensitive disease.
The Pennsylvania-based laboratory will integrate Ibex's AI solution for prostate biopsies and TURP specimens into its existing digital pathology infrastructure.
PROSTOX ultra identifies patients at higher risk of developing late genitourinary toxicity from stereotactic body radiation therapy.
Read More
Study finds molecular signature identifies which men with recurrent disease respond to apalutamide plus salvage radiation therapy.
Read More
Phase 3 STAMPEDE trial data demonstrates Decipher Prostate test can predict docetaxel treatment benefit, potentially helping patients avoid unnecessary toxicity.
Read More
The risk stratification tool is designed to predict long-term outcomes for patients with non-metastatic prostate cancer.
Read More
Fellow Health showcased innovative research, emphasizing mail-in semen testing to enhance prostate cancer diagnostics and PVSA care.
Read More
Veracyte has launched Decipher Prostate test, a Medicare-covered test for guiding treatment in metastatic prostate cancer.
Read More
A new study confirms Cleveland Diagnostics’ IsoPSA test effectively differentiates between low- and high-risk prostate cancer patients.
Read More
Decipher Prostate Genomic Classifier data is included in a new SEER Program database, enabling the study of prostate cancer outcomes.
Read More
Lynx Dx announced at-home availability of a urine-based prostate cancer test that eliminates the need for a digital rectal exam.
Read More
A new study validated a urine test that offers a less invasive, more accurate alternative to traditional prostate cancer screening.
Read More
A review found gaps remain for genomic classifier tests for their cost-effectiveness, clinical utility, and impact on diverse populations.
Read More
The AR-ctDETECT test identifies circulating tumor DNA in advanced prostate cancer patients, providing critical insights for prognostication.
Read More
A genetic variant in the PSA gene may help improve prostate cancer diagnostics by distinguishing between aggressive and non-aggressive types.
Read More
A study shows that measuring CTCs at the time of metastatic prostate cancer diagnosis can predict survival and guide treatment decisions.
Read More
A new prostate cancer screening method could help better predict which patients need to undergo a biopsy, reducing unnecessary procedures.
Read More